The article discusses how efforts to help developing countries get affordable medicines have limitations. Trade agreements like TRIPS aim to balance access to medicines with protecting intellectual property. Developing countries can import drugs under compulsory licenses, but this may not always work well. Some pharmaceutical companies abuse the system to delay competition. This can happen internationally too. The lack of competition rules and costs of following TRIPS can be tough for developing countries. Compulsory licensing can make it harder for them to get needed medicines.